U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Zn
Molecular Weight 65.3956
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of ZINC CATION

SMILES

[ZnH2+2]

InChI

InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N
InChI=1S/Zn/q+2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.3956
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zinc oxide is an inorganic compound with the formula ZnO. ZnO is a white powder that is insoluble in water, and it is widely used as an additive in numerous materials and products including rubbers, plastics, ceramics, glass, cement, lubricants, paints, ointments, adhesives, sealants, pigments, foods, batteries, ferrites, fire retardants, and first-aid tapes. Although it occurs naturally as the mineral zincite, most zinc oxide is produced synthetically. Zinc oxide is widely used to treat a variety of skin conditions, including dermatitis, itching due to eczema, diaper rash and acne. It is used in products such as baby powder and barrier creams to treat diaper rashes, calamine cream, anti-dandruff shampoos, and antiseptic ointments. It is also a component in tape (called "zinc oxide tape") used by athletes as a bandage to prevent soft tissue damage during workouts. Zinc oxide can be used in ointments, creams, and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light (see sunscreen). It is the broadest spectrum UVA and UVB absorber that is approved for use as a sunscreen by the U.S. Food and Drug Administration (FDA), and is completely photostable. When used as an ingredient in sunscreen, zinc oxide blocks both UVA (320–400 nm) and UVB (280–320 nm) rays of ultraviolet light. Zinc oxide and the other most common physical sunscreen, titanium dioxide, are considered to be nonirritating, nonallergenic, and non-comedogenic. Zinc oxide nanoparticles can enhance the antibacterial activity of ciprofloxacin. It has been shown that nano ZnO which has the average size between 20 nm and 45 nm can enhance the antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coli in vitro. The enhancing effect of this nanomaterial is concentration dependent against all test strains. This effect may be due to two reasons. First, zinc oxide nanoparticles can interfere with NorA protein, which is developed for conferring resistance in bacteria and has pumping activity that mediate the effluxing of hydrophilic fluoroquinolones from a cell. Second, zinc oxide nanoparticles can interfere with Omf protein, which is responsible for the permeation of quinolones into the cell.

Originator

Curator's Comment:: The use of pushpanjan, probably zinc oxide, as a salve for eyes and open wounds, is mentioned in the Indian medical text the Charaka Samhita, thought to date from 500 BC or before. Zinc oxide ointment is also mentioned by the Greek physician Dioscorides (1st century AD.)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
2002 Mar 1
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
Erythrocyte zinc content in critically ill patients.
2005
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].
2005
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
2014 May
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014 May 15
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015 Sep
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Recommended Dietary Allowance (RDA)-expressed as elemental zinc: 19 years and older: Male: 11 mg (Upper intake limit: 34 mg); Female: 9 mg (Upper intake limit: 34 mg); Pregnancy: 11 mg (Upper intake limit: 40 mg); Lactation: 12 mg (Upper intake limit: 40 mg) Zinc sulfate injection: IV: Metabolically stable adults receiving TPN: 2.5 to 4 mg zinc/day Acute catabolic states on TPN: Additional 2 mg zinc per day is recommended. Stable adult with fluid loss from the small bowel: Additional 12.2 mg zinc/liter of small bowel fluid lost, or an additional 17.1 mg zinc/kg of stool or ileostomy output is recommended.
Route of Administration: Other
HeLa, COS-7, and HEK293-T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS, Invitrogen), glutamine (2 mM), penicillin (100 units/mL), and streptomycin (100 μg/mL). Two days before imaging, the cells were passed and plated on untreated (HeLa, COS-7) 10-mm glass coverslips or on glass coverslips coated with 0.2% gelatin for at least 1 h at room temperature (HEK293-T). For labeling, the growth medium was removed and replaced with DMEM containing 1% FCS. The cells were treated and incubated with 10 μM sensor at 37 °C under 5% CO2 for 30 min. The cells were washed once with and bathed in DMEM containing no FCS prior to imaging and/or zinc addition. Zinc was introduced to the cultured cells as the pyrithione salt using a Zn (II)/pyrithione ratio of 1:1 or 1:2. Stock solutions of ZnCl2 (10 mM) and sodium pyrithione (20 mM) in DMSO were combined and diluted 10-fold with DMEM prior to addition. In a typical experiment, a 100-μL aliquot of this solution was added to the cells bathed in 2 mL of DMEM. A stock solution of TPEN (10 or 20 mM) was also diluted 10-fold with DMEM containing no FCS prior to cell treatment.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:26:35 UTC 2021
Edited
by admin
on Fri Jun 25 21:26:35 UTC 2021
Record UNII
13S1S8SF37
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CATION
Common Name English
ZINC ION
Common Name English
ZINC(II)
Systematic Name English
ZINC ION(2+)
Common Name English
ZINC(2+)
Systematic Name English
ZINC, ION (ZN2+)
Common Name English
Classification Tree Code System Code
NDF-RT N0000175530
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
WHO-ATC D09AB01
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
NCI_THESAURUS C68295
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
NCI_THESAURUS C597
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
DSLD 137 (Number of products:9660)
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
Code System Code Type Description
FDA UNII
13S1S8SF37
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
DRUG BANK
DB14532
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
NDF-RT
N0000175529
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY Decreased Copper Ion Absorption [PE]
PUBCHEM
32051
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
RXCUI
1546264
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C68296
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
CAS
23713-49-7
Created by admin on Fri Jun 25 21:26:35 UTC 2021 , Edited by admin on Fri Jun 25 21:26:35 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
LIGAND->TARGET
Scientific Literature
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY